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a  b  s  t  r  a  c  t
The  limited  durability  of  pertussis  vaccine-induced  protection  requires  novel  approaches  to  reactivate
immunity  and limit  pertussis  resurgence  in older  children  and  adults.  We  propose  that periodic  boosters
could  be  delivered  using  a novel  epicutaneous  delivery  system  (Viaskin®) to  deliver  optimized  pertussis
antigens  such  as  genetically-detoxiﬁed  pertussis  toxin  (rPT).  To  best  mimic  the  human  situation  in  which






murine  model  of pertussis  immunity.  This  allowed  demonstrating  that  a single  application  of Viaskin
delivering  rPT  and/or  pertactin  and ﬁlamentous  hemagglutinin  effectively  reactivates  vaccine-induced
pertussis  immunity  and  protects  against  Bordetella  pertussis  challenge.  Recalling  pertussis  immunity
without  needles  nor  adjuvant  may  considerably  facilitate  the  acceptance  and  application  of  periodic
boosters.
ublisdjuvant-free © 2015  The  Authors.  P
. Introduction
Bordetella pertussis is a respiratory pathogen readily transmitted
cross all ages. The widespread use of whole-cell pertussis vac-
ines resulted in a dramatic reduction of pertussis incidence in
hildren [1]. Unfortunately, their reactogenicity limited their use
n adolescents and adults and fears of brain damage affected public
onﬁdence, leading to their progressive replacement by less reac-
ogenic acellular pertussis (aP) vaccines [1]. However, an increase
f pertussis incidence was reported, mostly in aP vaccine-using
ountries [2], calling for a better control of pertussis [3]. As immu-
ity acquired through immunization or infection is short-lived [4],
Abbreviations: AlOH, aluminum hydroxide; aP, acellular pertussis; AUC, area
nder the clearance curve; B. pertussis, Bordetella pertussis; CFU, colony-forming
nits; DTaP-IPV, diphtheria-tetanus-acellular pertussis and poliomyelitis; EDS, epi-
utaneous delivery system; EPIT® , epicutaneous immunotherapy; FHA, ﬁlamentous
emagglutinin; HRP, horseradish peroxidase; LCs, Langerhans cells; OVA, oval-
umin; PRN, pertactin; PT, pertussis toxin; rPT, genetically-detoxiﬁed recombinant
T.
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particularly with aP vaccines, its reactivation requires repeat boost-
ing [4]. Novel strategies would thus be welcome.
The use of poorly immunogenic chemically-detoxiﬁed pertus-
sis toxin (PT) likely contributes to limit pertussis immunity [5]: it
removes up to 80% of surface epitopes, reducing neutralizing anti-
bodies, and directing B cells toward vaccine-speciﬁc rather than
pathogen-speciﬁc epitopes [6]. PT with wild-type immunogenic-
ity proﬁle but deprived of toxicity is best achieved through genetic
rather than chemical detoxiﬁcation [6–8].
The skin hosts a readily accessible network of dendritic cells
[9,10]. A large number of delivery devices have been developed
for the transcutaneous delivery of antigens [11]. This is however
limited by (i) the need to increase skin permeability through
mechanical or chemical disruption of the stratum corneum and
(ii) the requirement for potent adjuvants, which are not deprived
of adverse reactions and safety concerns [11,12]. In contrast, a
novel epicutaneous delivery system (EDS) (Viaskin®, DBV Tech-
nologies, Paris, France) currently in clinical trial for allergen
desensitization (http://www.dbv-technologies.com/en/investor-
relations/regulated-information/1687,First-patient-MILES) gen-
erates an occlusive chamber when applied to the intact skin: the
perspiration-induced moisture releases the proteins homoge-
nously sprayed on the membrane by electrospray, promoting their
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iffusion across the stratum corneum toward the epidermis [13].
revious experiments with ﬂuorescently labeled ovalbumin (OVA)
ave shown that a 48 h application on intact skin is efﬁcient for
nternalization and transport of the antigen, which is essentially
aken up by skin Langerhans cells (LCs), to the draining lymph
odes (dLNs) and activation of local immune cells [14,15]. The role
f LCs in Germinal Center formation and antibody responses was
ecently emphasized by Zimara et al. [16].
Here, we used genetically-detoxiﬁed recombinant PT (rPT), per-
actin (PRN) and ﬁlamentous hemagglutinin (FHA) sprayed on
iaskin® to reactivate vaccine-induced pertussis immunity in the
bsence of adjuvant. This was addressed through the development
f a murine model combining adoptive immunity transfer, immu-
ization and B. pertussis challenge to assess the reactivation of
emory in the absence of anti-pertussis antibodies.
. Material and methods
.1. Mice
Adult BALB/c female mice from Charles River (France) were
ept in pathogen-free animal facilities in accordance with local
uidelines. Experiments were conducted under relevant Swiss and
uropean guidelines and approved by the Geneva Veterinary Ofﬁce
GE/99/14) and the French Veterinary Services (2012 096) and Eth-
cal Committee CEEA-26.
.2. Antigens, adjuvants, immunizations
BALB/c mice were primed intramuscularly in both hind legs
ith 10 g OVA (Grade VI, Sigma) (n = 5) adsorbed onto 0.25 mg
luminum hydroxide (AlOH) (gift from Novartis Vaccines and Diag-
ostics, Siena, Italy) (OVA/AlOH) or with 1/5th of a human dose
50 L per hind leg) of a pediatric diphtheria-tetanus-acellular
ertussis-poliomyelitis (DTaP-IPV) vaccine (Infanrix Tetra®, Glax-
SmithKline) (n = 20–49) containing 25 g of PT, 25 g of FHA,
 g of PRN in addition to tetanus toxoid, diphtheria toxoid and
nactivated polioviruses. This protocol has been described to best
orrelate with pertussis vaccine efﬁcacy in human clinical trials
17]. Mice were bled on days 27, 49 and 63 post-prime (OVA) or on
ays 28 and 42 (pertussis antigens) for antibody determination.
ig. 1. Epicutaneous reactivation of OVA-speciﬁc antibodies. Naïve BALB/c mice were pr
ither  i.m. with OVA/AlOH (n = 5) (A) or with OVA/EDS (n = 5) (B) and bled on days 27, 49 an
o  naïve mice (n = 5) (cut-off value were deﬁned as pooled naïve mouse sera, dashed line). 
enerating similar results, 5 mice per group. Statistical analysis was performed using the33 (2015) 3450–3455 3451
2.3. Adoptive transfer of memory B cells
Donor mice were sacriﬁced 6 weeks after DTaP-IPV priming
and their spleens were harvested to prepare red blood cells-
depleted single-cell suspensions. 90 × 106 or 50 × 106 splenocytes
(in 100 L) were transferred intravenously into each naive BALB/c
recipient. Recipients were bled 6 days after transfer to quantify
passively transferred PT antibodies.
2.4. Epicutaneous antigen delivery
Viaskin® EDS containing 100 g OVA (Grade VI, Sigma)
were prepared as described [14,18]. The rPT (batch number
FE08/2013), FHA (batch number FE08/2013) and PRN (batch num-
ber FE08/2013) antigens produced from B. pertussis were provided
by BioNet-Asia Co., Ltd. (Bangkok, Thailand). Antigens were puriﬁed
as described [8] and resuspended in 1 mM Tris, 2 mM NaCl, 0.5 M
urea, 0.5 mg/mL  Brij-20, 1.4 mg/mL  histidine. Antigen integrity was
conﬁrmed by SDS–PAGE.
Hair was removed from the back of mice as described [18,19].
Twenty-four hours later, Viaskin® EDS were applied for 48 h on the
intact skin of their back [14,15].
Twenty eight days after priming or 1 week after adoptive trans-
fer, mice were boosted in groups of 5 with Viaskin® EDS containing
OVA (100 g) (OVA/EDS), rPT (25 g) (rPT/EDS), or 25 g each of
rPT, PRN and FHA (3-component pertussis (3cP)/EDS). Control mice
(n = 5) were left unboosted or received 1/5th of a human dose (50 L
per hind leg) of an aluminum-adsorbed booster dTpa (diphthe-
ria toxoids, tetanus and acellular pertussis) formulation (Boostrix
dTpa®, GlaxoSmithKline) containing 8 g of PT and FHA and 2.5 g
of PRN, in addition to tetanus and diphtheria toxoids. Serum sam-
ples were collected on days 7, 14 and 28 to evaluate antigen-speciﬁc
antibodies.
2.5. Quantiﬁcation of serum antigen-speciﬁc antibodies
Serum samples were obtained at the indicated time points (OVA:
days 27, 49 and 63; pertussis: days 7, 14, 20 or 28 post-boost) for
antibody detection by ELISA.
Plates were coated with 5 g/mL OVA (Grade VI, Sigma) in
phosphate-buffered saline (PBS) and blocked with 0.05% Tween and
imed i.m. at day 0 with OVA/AlOH. Mice were boosted on days 28 and 49 (arrows)
d 63 for determination of serum IgG1 and IgG2a OVA-speciﬁc antibodies compared
Data are represented as mean ± SEM, and representative of one of two experiments
 paired t test.






















































Fig. 2. Reactivation of anti-PT immune memory. (A), Cartoon illustration of adop-
tive transfer protocol of pertussis memory. Naïve BALB/c mice were primed i.m. with
DTaP-IPV/AlOH (n = 20), bled 4 weeks after priming (day 28), sacriﬁced 42 days post-
priming and their spleens harvested for adoptive transfer. 90 × 106 splenocytes per
mouse were transferred intravenously into naïve BALB/c recipients (day-7). These
were bled 6 days after transfer (day-1) to quantify passively transferred PT anti-
bodies. One day later (day 0), recipients were boosted with dTpa/AlOH (i.m.) (n = 5)
or  rPT/EDS (n = 5), or left unboosted (n = 5). Mice were bled on days 7, 14 and 28
for the determination of IgG1 (B) and IgG2a (C) anti-PT speciﬁc antibodies. Control452 B.M. Gavillet et al. / Va
% bovine serum albumin (BSA) (Sigma) prior to incubation with
-fold dilutions of individual mouse serum. Plates were incubated
ith secondary horseradish peroxidase (HRP)-conjugated anti-
ouse antibodies directed against IgG1 or IgG2a (Zymed) prior to
ncubation with 2,2′-azinobis (3-ethylbenzthiazolinesulfonic acid)
ubstrate. For PT, PRN and FHA, plates were coated with 1 g
f PT or 2 g of PRN per mL  overnight at 4 ◦C or with 1 g of
HA per mL  for 3 h at 4 ◦C as described [20]. Speciﬁc antibodies
ere revealed with goat anti-mouse IgG (H + L)–HRP (Invitro-
en, Life Technologies), IgG1 (BD Pharmingen) or IgG2a (Southern
iotech). The optical density of each well was determined with a
pectraMax (Molecular Devices) reader at 450 nm.  Results were
xpressed by reference to serial dilutions of a titrated pool of serum
standard serum) from OVA or DTaP-IPV immunized adult mice.
ntibodies below the cutoff of the assay were given an arbitrary
iter of one-half of the cutoff value to allow calculation of end-
oint titers by reference to the standard serum included in each
ssay.
.6. B. pertussis challenge
Streptomycin-resistant B. pertussis [20,21] were grown on
ordet-Gengou agar (Difco) plates supplemented with 1% glycerol
Amresco), 10% deﬁbrinated sheep blood (Chemie Brunschwig AG)
nd streptomycin (100 g/ml) at 37 ◦C for 24 h.
Twenty microliters of bacterial suspension (approximately
 × 106 colony-forming units (CFU)) was instilled intranasally
nder anesthesia induced by Ketasol® (Graeub) and Rompun®
Bayer). Mice were sacriﬁced 3 h, 2 and 7 days later to quantify
iable B. pertussis in the lungs, as described [20]. Lung homogenates
ere spread on agar plates and incubated for 4 days at 37 ◦C. B.
ertussis colonies were counted to calculate the number of CFU
er lung. The ratio of the area under the clearance curve (AUC)
f immunized and naïve control mice, a measure of protective efﬁ-
acy, was expressed as AUC (AUC naïve mice/AUC immunized
ice) [20].
.7. Statistical analysis
The GraphPad PRISM (6.01) software was used for statistical
nalysis. Results were expressed as mean ± SEM. Statistical analysis
etween results obtained from various group of mice was  per-
ormed using the paired t test or a two-tailed Wilcoxon signed rank
est (*, p value (0.01–0.05), **, p value (0.001–0.01), ***, p value
<0.001), ****, p value (<0.0001)). Differences with p > 0.05 were
onsidered to be insigniﬁcant.
. Results
.1. Boosting antigen-speciﬁc immunity through intact skin in
he absence of adjuvant
To deﬁne whether a single Viaskin® EDS application could
eactivate vaccine-induced immunity, we ﬁrst used the OVA model
ntigen. Adult BALB/c mice were primed i.m. with OVA/AlOH, and
oosted 28 days later with OVA/AlOH or with a 48 h application
f OVA/EDS. Anti-OVA IgG1 and IgG2a serum antibodies increased
arkedly after OVA/AlOH boosting (IgG1; day 27: 4.4 ± 0.04 log10;
ay 49: 5.5 ± 0.09 log10, p = 0.0007; IgG2a; day 27: 1.4 ± 0.0 log10;
ay 49: 1.9 ± 0.27 log10, p = 0.1319) (Fig. 1A). Their increase was
lso signiﬁcant in OVA/EDS-boosted mice (IgG1; day 27: 4.4 ± 0.14
og10; day 49: 5.0 ± 0.09 log10, p = 0.0081; IgG2a; day 27: 1.4 ± 0.0
og10; day 49: 2.3 ± 0.18 log10, p = 0.0076) (Fig. 1B). A second boost
n day 49 did not further increase anti-OVA antibodies.naïve mice were only primed with dTpa/AlOH on day 0 (n = 5). Data are represented
as mean ± SEM, and representative of one of two  experiments generating similar
results. Statistical analysis was  performed using the paired t test.
3.2. Epicutaneous reactivation of pertussis vaccine-induced
immunity
To explore the capacity of Viaskin® EDS to reactivate pertus-
sis immunity, rPT was sprayed on Viaskin® EDS and used to boost
DTaP-IPV primed mice. In this experimental setting, the presence of
high IgG1 antibodies elicited by DTaP-IPV/AlOH priming prevented
the precise quantiﬁcation of the booster response (data not shown).
To mimic  the human condition in which immunization-
or infection-induced memory cells persist along with low or
absent anti-PT antibodies [22], we developed an adoptive trans-
fer murine model (Fig. 2A). Anti-PT antibodies reached high titers
in DTaP-IPV/AlOH-primed donor mice (6 weeks post-priming:
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ut were undetectable in recipients 6 days after splenocytes
ransfer (D-1), conﬁrming the lack of antibody transfer (Fig. 2B
nd C). Without boosting, anti-PT antibodies increased slowly
IgG1) or remained undetectable (IgG2a). Within one week of
Tpa/AlOH immunization, anti-PT antibodies increased to signiﬁ-
antly higher titers than baseline in transfer recipients (IgG1 day
: 4.89 ± 0.04 log10 vs 2.00 ± 0.0 log10, p < 0.0001; IgG2a day 7:
.21 ± 0.07 log10 vs 1.7 ± 0.0 log10, p < 0.0001), but not in naïve
ontrol mice primed with dTpa/AlOH on day 0 (Fig. 2B and C).
ne single rPT/EDS application also reactivated anti-PT antibod-
es to signiﬁcantly higher titers than baseline within 7 days (IgG1
ay 7: 2.92 ± 0.15 log10 vs 2.00 ± 0.0 log10, p = 0.0039; IgG2a day
: 1.78 ± 0.084 log10 vs 1.7 ± 0.0 log10, p = 0.3739), and to high
iters within 2 weeks (IgG1 day 14: 4.60 ± 0.124 log10 vs day 28
.84 ± 0.133 log10, p = 0.0008; IgG2a day 14: 2.99 ± 0.188 log10 vs
ig. 3. Reactivation of protective pertussis immunity. Naïve BALB/c mice were primed w
ere  transferred i.v. with 50 × 106 splenocytes per mouse and bled 6 days after transfer (d
day  0), recipients were boosted with dTpa/AlOH () (n = 15) or 3cP/EDS (©) (n = 15), or le
oosting for the determination of PT-(A), PRN-(B) and FHA-(C) antibodies. Serum from naïv
epresented as mean ± SEM, and representative of one of two experiments generating sim
ank  test. (D), Kinetics of B. pertussis clearance from the lungs after respiratory challenge. 
.  pertussis and sacriﬁced at various intervals (5 mice per group and 3 naïve mice per tim
xpressed as mean ± SD viable B. pertussis counts at the indicated time points.33 (2015) 3450–3455 3453
day 28 3.08 ± 0.18 log10, p = 0.0075) (Fig. 2B and C). Thus, rPT/EDS
triggered the rapid reactivation and differentiation of vaccine-
induced PT-speciﬁc memory B cells into IgG1 and IgG2a-secreting
plasmocytes.
3.3. Reactivation of protective pertussis immunity through
epicutaneous immunization
B. pertussis is a complex pathogen and most vaccines include
several pertussis antigens. Thus, recipient mice were next boosted
with a 3-component pertussis (3cP)/EDS including rPT, FHA and
PRN: this triggered within one week similarly high IgG, IgG1 and
IgG2a anti-PT and PRN antibodies as a dTpa/AlOH booster (Fig. 3A
and B). Anti-FHA antibodies also signiﬁcantly increased within one
week, although to signiﬁcantly lower titers even at day 20 (IgG
ith DTaP-IPV/AlOH and their spleens harvested 6 weeks later (n = 49). Recipients
ay-1) to quantify passively transferred PT-, PRN-, and FHA-antibodies. One day later
ft unboosted () (n = 15). Serum samples were collected on days 7, 14 and 20 after
e mice (n = 9) were considered as the cut-off indicated by the dashed lines. Data are
ilar results. Statistical analysis was performed using a two-tailed Wilcoxon signed
Three weeks post-boost (day 21), recipient mice were challenged intranasally with
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ay 20: 4.19 ± 0.11 log10 vs 5.06 ± 0.05 log10, p = 0.0005) than in
Tpa/AlOH boosted recipients (Fig. 3C).
To conﬁrm that 3cP/EDS reactivated functional immunity, recip-
ent mice were challenged intranasally with B. pertussis 21 days
fter 3cP/EDS or dTpa/AlOH boosting. Bacterial loads remained
igh in the lungs of naive or non-boosted recipient mice (Fig. 3D).
n contrast, a similarly rapid bacterial decline was  observed
n the lungs of recipient mice boosted with either 3cP/EDS or
Tpa/AlOH prior to challenge (AUC: 3cP/EDS: 21.55 ± 0.44 vs
Tpa/AlOH: 16.32 ± 0.33) (Fig. 3D). Thus, protective immune mem-
ry against pertussis was reactivated through a single needle-free
nd adjuvant-free epicutaneous immunization.
. Discussion
Using a new murine model, we show that pertussis immune
emory may  be reactivated by a single application of an adjuvant-
ree novel EDS and confer protective immunity.
Murine B. pertussis infection models present many features sim-
lar to those observed in humans [23] and B. pertussis clearance in
mmunized mice correlates with pertussis vaccine efﬁcacy in chil-
ren [24]. However, murine antibodies reach and persist at high
iters after a single immunization, a condition distinct from the
ersistence of immune memory but waning of anti-PT antibod-
es prevailing in humans [22]. To reproduce this condition, we set
p an adoptive transfer model in which immune splenocytes are
ransferred to syngeneic recipients prior to immunization and/or
hallenge (Fig. 2). This model (i) effectively transfers immune mem-
ry, demonstrated by the rapid (1 week) and strong increase of
gG antibodies following boosting; (ii) avoids the persistence of
erum antibodies and (iii) does not transfer a signiﬁcant number
f plasma cells, as reﬂected by the minimal increase of antibod-
es in the absence of boosting. Antibody responses and protection
nduced by the immunization of recipient mice thus reﬂect the
eactivation of transferred memory B cells and their differentia-
ion into IgG-producing antibody-secreting-cells. Further work will
ecipher how various types and numbers of memory B and T cells
nﬂuence boosting capacity.
Using this adoptive transfer model, we demonstrate that epicu-
aneous immunization may  reactivate vaccine-induced immunity
n intact skin and in the absence of adjuvant. Our adjuvant-free
pproach was based on the distinct activation requirements of
emory and naive B cells [25–27]: memory B cells expressing
g-speciﬁc surface IgG bind antigens with a higher afﬁnity [28]
nd thus require lower antigen concentrations and lower T cell
elp than naive B cells [29]. We  postulated that this may  enable
he reactivation of immune memory in the absence of adjuvant, a
ypothesis conﬁrmed with OVA and 3 pertussis antigens.
The efﬁcient uptake, internalization and transport of antigens
o the draining lymph nodes by skin LCs [14,15] is likely to play a
ritical role [16]. Skin stripping prior to EDS application classically
ncreases antigen diffusion [14,15]. However, it did not enhance
nti-OVA responses (data not shown), suggesting that antigen
elivery is not a limiting factor of the Viaskin® EDS. This is also
upported by the similar boosting capacity of single or repeat EDS
pplications. The combination of 3 antigens did not interfere and
ather increased anti-PT antibodies, perhaps as a result of enhanced
ystander T cell help from follicular T helper cells. Further inves-
igations will deﬁne the exact mechanisms at play, the minimal
mount of antigen required on the EDS and the optimal ratio of
PT, FHA and PRN.The effective delivery of antigens through the Viaskin® EDS
nd unique properties of rPT are likely to both contribute to the
uccess of our approach. Indeed, the use of rPT improves protective
fﬁcacy against wild-type strains [6]. A recent clinical study33 (2015) 3450–3455
indicated that boosting with rPT was safe and induced signiﬁcantly
higher neutralizing antibodies than current acellular pertussis vac-
cines (BioNet forthcoming data, http://www.businesswire.com/
news/home/20141015006848/en/BioNet-Update-Recombinant-
Acellular-Pertussis-Vaccine-BioJapan#.VGK69skVji0).
Our study has limitations. Murine models do not recapitulate all
the features of human pertussis infection, which is best studied in
nonhuman primates or human challenge studies [30]. Human skin
is thicker and less hairy [31] than murine skin: despite a comparable
density of dendritic cells, their deeper localization in humans may
limit their targeting [32]. However, the Viaskin® EDS was demon-
strated as a sensitive tool for the diagnosis of cow’s milk [13] and
house dust mites [33] allergy in children, for which it is in clinical
use in France. Encouraging results have been collected for its use
in epicutaneous immunotherapy (EPIT) [15,18,19], and the safety
and efﬁcacy of Viaskin®-mediated EPIT against peanut allergy was
demonstrated in a recent phase IIb clinical trial [34].
Our observations therefore raise considerable hopes that this
needle-free, adjuvant-free EDS may  prove an efﬁcient antigen-
delivery-system for periodic boosting of pertussis immunity,
addressing an unmet need. It could increase injection safety, be
rapidly administered by non-injection-trained staff, improve com-
pliance by reducing fears and injection-associated pain and address
the unfounded but growing concerns related to the repeat use
of aluminum adjuvants, especially during pregnancy. A proof-of-
concept Phase I clinical study is thus in preparation.
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